Detail akcie Bioline RX RSp ADR online

Business Summary: BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, BioLine RX Ltd - ADR revenues increased from $0K to $17.2M. Net loss decreased 87% to $6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Non-operating Income/Expenses, Net increase from $13.8M (expense) to $13.1M (income), Research and development expenses decrease of 23% to $7.3M (expense).